Relationships between oral mucositis and treatment variables in bone marrow transplant patients.
The pattern of oral mucositis and related treatment variables was studied in 20 bone marrow transplant patients. Patients received either total body irradiation (TBI) or busulfan in combination with cyclophosphamide and etoposide as pretransplant conditioning. Daily oral assessment scores were analyzed. Mucosal changes began approximately 2 days before transplant and peaked approximately 8 days after transplant. There was a trend for patients receiving TBI to have slightly higher oral scores during the first week posttransplant than patients receiving busulfan. The TBI patients averaged almost twice the number of days of continuous intravenous morphine infusion for oral pain and 6 additional days of total parenteral nutrition when compared with patients receiving busulfan. Subjects who died during aplasia manifested mucositis that gradually worsened and did not return to baseline. Differences in oral status based on type of transplant, either autologous or allogeneic, were not shown in this study.
Zerbe
M B
MB
Georgetown University School of Nursing, Washington, D.C. 20007.
Parkerson
S G
SG
Ortlieb
M L
ML
Spitzer
T
T
D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000379:methods; D002066:Busulfan / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D004219:District of Columbia / Q000453:epidemiology; D005047:Etoposide / Q000009:adverse effects; D005260:Female; D006785:Hospitals, University; D006801:Humans; D008297:Male; D008875:Middle Aged; D009730:Nursing Assessment / Q000379:methods; D010865:Pilot Projects; D012307:Risk Factors; D012720:Severity of Illness Index; D013280:Stomatitis / Q000453:epidemiology* / Q000209:etiology / Q000451:nursing; D014916:Whole-Body Irradiation / Q000009:adverse effects
D005047:Etoposide; D003520:Cyclophosphamide; D002066:Busulfan